News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


   Share  

Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.


Posted on: 03/18/2008

J Neurooncol. 2008 Mar 4; [Epub ahead of print]


Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance status.

Ducray F, Benouaich-Amiel A, Idbaih A, Rousseau A, Laigle-Donadey F, Delattre JY, Sanson M.

INSERM, Unite U711, Universite Pierre et Marie Curie Paris VI, 47-83 Boulevard de l'Hopital, 75013, Paris, France.

There is no standard of care for elderly patients with glioblastoma (GBM) and poor performance status. A 79-year-old woman with GBM, aphasia, and hemiplegia achieved a complete response after only one cycle of temozolomide (TMZ) (150 mg/m(2)/day over 5 days). Genomic profiling of the tumor demonstrated loss of chromosome 10 and MDM2 amplification, which are predictive of poor outcome. The MGMT promoter was methylated, and it is likely that this at least partially explains the exquisite chemosensitivity in our patient. This unusual case report suggests that TMZ warrants further investigation in elderly patients with poor performance status.

PMID: 18317694 [PubMed - as supplied by publisher]

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2017 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites